Skip to main content

Remote Job Finders (RJF)

The Alchemab deal will further strengthen Lilly’s early-stage pipeline for amyotrophic lateral sclerosis, coming less than a year after the pharma licensed QurAlis’ antisense oligonucleotide to correct a specific protein alteration in ALS.
Lilly Deepens ALS Pipeline With $415M Alchemab Licensing Deal
Scroll to top